598384 The present disclosure relates to 3-deazapteridinone derivatives (i.e. having the core structure 3,4-Dihydropyrido[3,4-b]pyrazin-2(1H)-one or Pyrido[3,4-b]pyrazine-2,3-diol) of formula I as modulators of Toll-Like Receptors (TLR), compositions containing such compounds, therapeutic methods that include the administration of such compounds. Conditions which may be treated with said compounds include viral infections, melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza. In the case viral infections the administration of the compounds may result in reduction in viral load or clearance of RNA.
